How much Bacillus subtilis R0179 should I take per day?

Clinical studies have used doses ranging from approximately 1×10^9 to 2×10^9 CFU per day, with fecal recovery data showing dose-dependent colonization at 4.6–6.4 log10 CFU/g of stool. Most commercial formulations containing this strain are dosed within this range, taken once daily with or without food, since the spore form is stable regardless of meal timing.

Does Bacillus subtilis R0179 actually survive stomach acid?

Yes—Bacillus subtilis R0179 forms heat- and acid-resistant endospores that withstand gastric pH as low as 2.0 and high bile salt concentrations in the duodenum. A randomized controlled trial in healthy adults confirmed fecal recovery of 4.6–6.4 log10 CFU/g, demonstrating that viable cells successfully transit the entire GI tract and are detectable in stool.

What bacteria does Bacillus subtilis R0179 increase in the gut?

Clinical data from an RCT show that Bacillus subtilis R0179 selectively increases Ruminococcaceae (Ruminococci), a family of anaerobic bacteria associated with healthy fiber fermentation and short-chain fatty acid production, particularly butyrate. Importantly, this increase occurred without significant disruption to overall microbiota diversity metrics, suggesting a targeted rather than broad ecological shift.

Is Bacillus subtilis R0179 safe for children or pregnant women?

Published safety data for Bacillus subtilis R0179 specifically in pediatric or pregnant populations are currently limited, and no formal clinical trials in these groups have been published as of the most recent literature. Pregnant or nursing individuals and parents considering probiotic supplementation for children should consult a healthcare provider before use, particularly because regulatory guidance on probiotic use during pregnancy remains cautious pending larger safety trials.

What is the difference between Bacillus subtilis R0179 and Bacillus coagulans?

Both are spore-forming probiotics with high GI survivability, but Bacillus subtilis R0179 and Bacillus coagulans are distinct species with different strain-specific mechanisms and evidence profiles. Bacillus coagulans (e.g., GBI-30, 6086) has more extensive clinical data for IBS and post-antibiotic recovery, while B. subtilis R0179 has emerging evidence specifically for Ruminococcaceae modulation and production of lipopeptides like iturin and surfactin with antimicrobial properties not well-documented for B. coagulans strains.

What clinical research supports the effectiveness of Bacillus subtilis R0179?

Bacillus subtilis R0179 has been studied in randomized controlled trials demonstrating high gastrointestinal viability with dose-dependent fecal recovery rates of 4.6-6.4 log10 CFU/g in healthy adults, providing strong evidence for its survival through the digestive tract. Research also shows moderate evidence that it modulates gut microbiota by selectively increasing beneficial Ruminococci bacteria while maintaining overall microbiota balance. These findings indicate that R0179 delivers viable organisms to the colon and produces measurable changes in beneficial bacterial populations.

Is Bacillus subtilis R0179 safe to use long-term at high doses?

Clinical trials have demonstrated excellent tolerance and safety for Bacillus subtilis R0179 at doses up to 10×10⁹ CFU/day for 4 weeks with no adverse effects reported in study participants. While short-term safety data is strong, individual tolerance may vary, and it is advisable to follow recommended dosing guidelines and consult a healthcare provider before extending use beyond studied durations. As with any probiotic, starting with standard doses and monitoring personal response is prudent practice.

Who should consider supplementing with Bacillus subtilis R0179?

Bacillus subtilis R0179 may benefit individuals seeking to support beneficial gut bacteria populations, particularly those interested in increasing Ruminococci species without disrupting overall microbiota composition. It is most appropriate for adults in generally good health who want to maintain or improve gut microbiota balance, though individuals with compromised immune systems or acute gastrointestinal conditions should consult a healthcare provider first. Its excellent tolerability profile makes it suitable for long-term supplementation in those without contraindications.

Bacillus subtilis R0179

Bacillus subtilis R0179 is a spore-forming probiotic strain whose heat-resistant endospores survive gastric acid transit, germinating in the intestine to modulate gut microbiota composition. It exerts its primary effects by selectively promoting Ruminococcaceae populations and producing antimicrobial lipopeptides such as iturin and surfactin that inhibit pathogenic organisms.

Category: Fermented/Probiotic Evidence: 2/10 Tier: Moderate

Bacillus subtilis R0179 — Hermetica Encyclopedia

Origin & History

Bacillus subtilis R0179 is a specific spore-forming probiotic strain isolated from soil and the human gastrointestinal tract, commercialized by Lallemand Health Solutions as Rosell®-179. It is produced via fermentation followed by sporulation for stability, classified as a GRAS (Generally Recognized as Safe) microorganism belonging to the Firmicutes phylum.

Historical & Cultural Context

No historical or traditional medicinal use is documented for B. subtilis R0179 or strain-specific applications in traditional systems. B. subtilis as a species lacks evidence of pre-modern use, emerging instead as a modern probiotic from natural soil and gastrointestinal isolation.

Health Benefits

• Demonstrates high gastrointestinal viability with dose-dependent fecal recovery (4.6-6.4 log10 CFU/g) in healthy adults (Strong evidence from RCT)
• Modulates gut microbiota by increasing beneficial Ruminococci bacteria without disrupting overall microbiota balance (Moderate evidence from RCT)
• Shows excellent tolerance with no adverse effects at doses up to 10×10⁹ CFU/day for 4 weeks (Strong safety evidence from RCT)
• Survives harsh GI conditions as spores that germinate into viable cells for gut colonization (Strong evidence from clinical trial)
• May provide antimicrobial benefits based on related B. subtilis strains, though R0179-specific antimicrobial data lacking (Preliminary evidence)

How It Works

Bacillus subtilis R0179 spores resist gastric acid and bile salts, germinating in the small intestine where vegetative cells produce antimicrobial lipopeptides—including iturin A, surfactin, and fengycin—that disrupt pathogen membrane integrity. Germinating cells also produce short-chain fatty acid precursors and enzymes such as amylase, protease, and lipase that support intestinal epithelial metabolism and mucosal barrier integrity. Additionally, the strain stimulates toll-like receptor 2 (TLR-2) and TLR-4 signaling on intestinal epithelial and dendritic cells, promoting balanced Th1/Th2 immune responses and upregulating secretory IgA production.

Scientific Research

A randomized, double-blind, placebo-controlled trial (n=81 healthy adults, NCT01802151; PMID: 25062611) tested B. subtilis R0179 at three doses (0.1×10⁹, 1×10⁹, or 10×10⁹ CFU/day) for 4 weeks, demonstrating dose-dependent GI viability and microbiota modulation. No RCTs or meta-analyses for therapeutic indications were identified, with evidence limited to safety and viability in healthy adults.

Clinical Summary

A randomized, double-blind, placebo-controlled trial in healthy adults demonstrated dose-dependent fecal recovery of Bacillus subtilis R0179 at 4.6–6.4 log10 CFU/g, confirming robust gastrointestinal viability across tested doses. The same RCT showed selective increases in beneficial Ruminococcaceae without statistically significant disruption of overall alpha or beta diversity, indicating a targeted rather than broad microbiota shift. Evidence for immune endpoints and gastrointestinal symptom relief is preliminary, largely derived from small pilot studies and in vitro models, and larger trials are needed to confirm these outcomes. Overall, the evidence base is moderate-to-strong for viability and microbiota modulation, but limited for clinical disease endpoints.

Nutritional Profile

Bacillus subtilis R0179 is a probiotic microorganism and not a conventional food ingredient with macronutrient or micronutrient content intended for direct nutritional contribution. As a bacterial strain delivered in CFU (colony-forming units), its nutritional profile is characterized by its bioactive components rather than macronutrients. Key bioactive compounds include: (1) Spore coat proteins and dipicolinic acid (DPA), which contribute to the strain's exceptional heat and acid stability, enabling survival through gastric transit with demonstrated fecal recovery of 4.6–6.4 log10 CFU/g at doses of 1×10⁹ to 10×10⁹ CFU/day; (2) Endogenous enzymes including proteases, amylases, and lipases produced during vegetative growth that may support luminal digestion; (3) Short-chain fatty acid (SCFA)-promoting activity via microbiota modulation, particularly through upregulation of Ruminococcus spp., which are known butyrate producers — estimated indirect contribution to luminal butyrate production rather than direct provision; (4) Bacteriocin-like inhibitory substances (BLIS) and lipopeptides (e.g., iturin, surfactin class compounds) produced by Bacillus subtilis species that contribute to competitive exclusion of pathogens; (5) Cell wall components including peptidoglycan and teichoic acids that act as immunomodulatory ligands for host pattern recognition receptors (TLRs). Typical delivery format contains negligible macronutrients (protein <1 mg/dose, fat <0.1 mg/dose, carbohydrates <1 mg/dose at standard CFU doses). No clinically significant vitamin or mineral contribution is associated with standard probiotic doses. Bioavailability note: spore-forming capability ensures approximately 100-fold greater gastrointestinal survivability compared to non-spore-forming lactobacilli, with viability maintained across pH 2–8 and temperatures up to 80°C.

Preparation & Dosage

Clinically studied doses range from 0.1×10⁹ to 10×10⁹ CFU/day in capsule form for 4 weeks. The most common dosage appears to be in the mid-range around 1×10⁹ CFU/day. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Enterococcus faecium R0026, Lactobacillus acidophilus, Bifidobacterium bifidum, Prebiotic fibers, Digestive enzymes

Safety & Interactions

Bacillus subtilis R0179 is generally regarded as safe for healthy adults, with no serious adverse events reported in published clinical trials at doses up to 2×10^9 CFU per day. Mild, transient gastrointestinal symptoms such as bloating or flatulence may occur during the initial days of supplementation as the gut microbiota adjusts. Immunocompromised individuals, those with central venous catheters, or patients recovering from major surgery should consult a physician before use, as spore-forming Bacillus species carry a theoretical—though rarely documented—risk of bacteremia in vulnerable populations. No clinically significant drug interactions have been established, but concurrent use with broad-spectrum antibiotics may reduce viability and efficacy; separating administration by at least two hours is advisable.